NATIONAL INSTITUTES OF HEALTH

The CABINET phase III trial showed cabozantinib significantly improved median progression-free survival (PFS) in previously treated neuroendocrine tumors (NETs), with 13.8 months for pNET and 8.4 months for epNET compared to 4.4 and 3.9 months for placebo, respectively. The results, presented at ESMO 2024 and published in NEJM, support cabozantinib as a potential new standard of care for advanced NET patients.

Suffian et al. found racial and ethnic disparities in food oral immunotherapy (FOIT) clinical trials, raising concerns about generalizability. They suggest addressing structural and social determinants of health to achieve health equity in FOIT research and practice.

The forced swim test (FST) and tail suspension test (TST) are criticized for inaccurately modeling human depression, leading to ineffective antidepressant development. Despite being deemed invalid for 15 years, these tests continue to be funded and published, despite evidence suggesting they are not reliable predictors of human responses to antidepressants. The UK and Australia have banned the FST, and the NIH is shifting towards non-animal-based research methods. An upcoming advisory council meeting could be pivotal in ending the use of these outdated tests.

Final results from the CABINET phase III trial show cabozantinib significantly improves median progression-free survival (PFS) in previously treated advanced neuroendocrine tumors (pNET and epNET), with PFS of 13.8 months vs 4.4 months for pNET and 8.4 months vs 3.9 months for epNET. The study also demonstrated benefits across all clinical subgroups and a safety profile consistent with previous findings, leading to an early unblinding of the trial and a supplemental new drug application for cabozantinib.

Cabometyx® (cabozantinib) showed significant reduction in disease progression or death risk in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs) compared to placebo, according to data from the CABINET Phase III trial. The results were presented at ESMO 2024 and published in the New England Journal of Medicine. Ipsen has submitted an extension of indication Marketing Authorization to the European Medicines Agency.

Cabometyx (cabozantinib) showed significant reduction in disease progression or death risk in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs) compared to placebo, according to final data from the CABINET Phase III trial. Ipsen has submitted an extension of indication Marketing Authorization to the European Medicines Agency. The data were presented at ESMO 2024 and published in the New England Journal of Medicine.

Final CABINET Phase III trial data showed Cabometyx significantly reduced disease progression or death risk in advanced pancreatic and extra-pancreatic neuroendocrine tumors (NETs) compared to placebo, presented at ESMO 2024 and published in NEJM. Ipsen has submitted an extension of indication Marketing Authorization to the EMA, addressing limited treatment options for advanced NETs.

Research focuses on precision treatment of tumors, particularly in radiation oncology, aiming to personalize radiation therapy doses using biomarkers like the NAR score and GARD model. These tools predict neoadjuvant radiotherapy efficacy and survival outcomes, suggesting individualized doses could improve treatment outcomes for locally advanced rectal cancer (LARC) patients.

A new 10-minute AI-powered blood test, IntelliSep, may soon be available in hospitals to diagnose sepsis, potentially saving lives by providing rapid and reliable detection.